Neoadjuvant treatment with docetaxel plus lapatinib (L), trastuzumab (T), or both followed by an anthracycline based chemotherapy in HER2-positive breast cancer: Results of the randomised phase II EORTC 10054 study
H. Bonnefoi
Neoadjuvant treatment with docetaxel plus lapatinib (L), trastuzumab (T), or both followed by an anthracycline based chemotherapy in HER2-positive breast cancer: Results of the randomised phase II EORTC 10054 study
H. Bonnefoi